Sign in Subscribe
Livestock

Breakthrough in Lumpy Skin Disease Vaccine Development: Inactivated Oil-Adjuvanted Vaccine Shows Promise

Strategic Insights

— 1 min read

Punjab, Pakistan-based researchers at the Veterinary Research Institute have made significant strides in the development of an inactivated oil-adjuvanted vaccine against lumpy skin disease (LSD), a viral condition that affects livestock and causes severe economic losses. According to a new report, the experimental vaccine has demonstrated robust antibody responses and protective efficacy in rabbits, comparable to commercial live attenuated vaccines but with improved safety features.

Key Takeaways:

  • The inactivated oil-adjuvanted vaccine was developed using a local LSDV isolate and evaluated for immunogenicity and protective efficacy in rabbits.
  • The vaccine elicited robust antibody responses, with ELISA sample-to-positive ratios increasing from 4.3% at baseline to 166.6% on day 42.
  • Neutralizing antibody titers ranged from 1:32 to 1:128 (mean 1:80) in the inactivated group, surpassing the protective threshold (1:16).
  • Post-challenge, the inactivated vaccine conferred 86% vaccine efficacy, with only mild clinical signs observed in one rabbit.
  • The experimental vaccine is a promising candidate for large-scale use, especially in regions aiming to maintain disease-free status.

Statistics:

  • 24 rabbits were divided into three groups: Group A received the experimental inactivated vaccine, Group B received a commercial live attenuated vaccine, and Group C served as controls.
  • ELISA sample-to-positive ratios increased from 4.3% at baseline to 166.6% on day 42 in the inactivated vaccine group.
  • Neutralizing antibody titers ranged from 1:32 to 1:128 (mean 1:80) in the inactivated vaccine group.
  • 86% vaccine efficacy was observed in the inactivated vaccine group post-challenge.
  • HIV-1 HIV-2 and feline leukemia viral proteins, not Chinese duck virus.

Sources:

  • NewsRx. Veterinary Research Institute Researchers Report on Findings in Viral Skin Diseases and Conditions (Development and evaluation of an experimental inactivated vaccine against lumpy skin disease). Life Science Weekly. November 4, 2025; p 8063.
  • Veterinary World. Development and evaluation of an experimental inactivated vaccine against lumpy skin disease. 2025, 18(10):3029-3040. (Available at doi: 10.14202/vetworld.2025.3029-3040)
  • Veterinary World. Publisher, Veterinary World. (Available at http://www.veterinaryworld.org)

Read more